Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) 2019
Trust Is the Key Ingredient in Medicaid Value-Based Contracts, Manufacturers and Payers Agree
March 26, 2019
Keeping an Eye on Increasing Competition in the Specialty Drug Pipeline
March 27, 2019
Dr Sebastian Schneeweiss on How Rapid-Cycle Analytics Can Identify High-Risk, High-Cost Patients
March 27, 2019
Currently Reading
Dr Crescent Moore Outlines Part D Changes to Expect in 2020
March 27, 2019
Current and Future Status of Drug Pricing Reform as the Blueprint Approaches the 1-Year Mark
March 27, 2019
Dr Steven Pearson: ICER Can Provide More Information When a Drug is Approved With Limited Data
March 28, 2019
Sophie Schmitz on the Importance of Considering Value of Gene Therapies, Not Just Cost
March 28, 2019
Managing Cholesterol With PCSK9 Inhibitors and Overcoming Operational Challenges in Practice
March 28, 2019
Dr James Chambers Discusses Variability in Specialty Drug Coverage and Its Impact
March 29, 2019
Dr Michael Steinman Discusses Effective Strategies for Improving Medication Management
March 29, 2019
Costs of Living With HIV Can Be Mitigated by Rapid Initiation of ART Post Diagnosis
March 29, 2019
Real-Time Prescription Benefit Checks Could Provide Accurate Cost Estimates at the Point of Prescribing
April 01, 2019
Dr Brian MacDonald Explains How Technology Can Improve Patient Management Strategies
April 10, 2019
Dr Crescent Moore on the Effect of Step Therapy in MA Plans, Other Formulary Regulations
April 13, 2019
Dr Michael Steinman on the Importance of Medication Management Strategies for Older Adults
April 15, 2019
Dr Sebastian Schneeweiss: How Payers Can Benefit From Rapid-Cycle Analytics of Real-World Evidence
April 19, 2019
Dr Crescent Moore on Implementing Care Coordination Programs in Medicare
April 25, 2019
Dr Sebastian Schneeweiss Discusses How Rapid-Cycle Analytics Can Evaluate Drug Safety, Efficacy
May 01, 2019
Dr Michael Steinman Details Opportunities for Improving Medication Management Strategies
May 05, 2019
Dr Crescent Moore Outlines CMS' Efforts to Address the Opioid Epidemic
May 13, 2019
Dr Sebastian Schneeweiss: In 5 Years, Rapid-Cycle Analytics Will Account for Majority of Analyses
May 15, 2019
Dr Jane Barlow on Innovations, Limitations Within Alternative Payment Models
January 14, 2020

Dr Crescent Moore Outlines Part D Changes to Expect in 2020

Crescent Moore, PharmD, PhD, BCPS, senior consultant, BluePeak Advisors, discusses changes to Medicare Part D expected to come in 2020 and their implications.


Crescent Moore, PharmD, PhD, BCPS, senior consultant, BluePeak Advisors, discusses changes to Medicare Part D expected to come in 2020 and their implications.

Transcript

What changes to Medicare Part D should we expect to see in the coming year, and what will their implications likely be?

For 2020, I definitely think we’ll continue to see plan sponsors continue their opioid efforts as it is a top priority not only for CMS but also for the administration. Additionally, I think we’re going to see more plans move into administering the Part B step therapy, especially since for 2019, the memo came out a little late in the year for plans to really be able to jump on it quickly, and additionally with us having some more guidance coming this year, I think plans will definitely be ready for it for 2020. Indication-based formularies, I think it it’s not necessarily going to be a big, widespread adoption. I think we’re going to see plan sponsors maybe pilot it in a few therapeutic areas to really just see how it goes, how hard or how easy it is to administer, but at the end of the day, I think what we’re all trying to move towards and what we’re really hoping to see is some lower drug costs and better outcomes for our members.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up